Literature DB >> 10771862

Hematological responses to hydroxyurea therapy in multitransfused thalassemic children.

V P Choudhry1, A Lal, H P Pati, L S Arya.   

Abstract

Fifteen multi-transfused thalassemic children between 3-6 years of age (seven boys and eight girls) were administered hydroxyurea for 5 days and three such cycles were repeated at 15 days interval. Rise in hemoglobin levels was observed in 13, 8 and 7 cases, while rise in mean hemoglobin F was seen in 8, 11 and 10 cases following 1st, 2nd and 3rd course of hydroxyurea therapy respectively. Rise in hemoglobin level was associated with transient rise in fetal hemoglobin level. Though the changes in mean hemoglobin levels and hemoglobin F levels were statistically insignificant, a definite trend of rise in hemoglobin and hemoglobin F was observed.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 10771862     DOI： 10.1007/bf02845212

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN： 0019-5456            Impact factor:   1.967


  11 in total

Review 1.  Developmental regulation of human globin genes.

Authors:  S Karlsson; A W Nienhuis
Journal:  Annu Rev Biochem       Date:  1985       Impact factor: 23.643

Review 2.  Developmental genetics of the human haemoglobins.

Authors:  W G Wood; D J Weatherall
Journal:  Biochem J       Date:  1983-10-01       Impact factor: 3.857

3.  5-azacytidine for beta-thalassemia?

Authors:  J B Clegg; D J Weatherall; W F Bodmer
Journal:  Lancet       Date:  1983-03-05       Impact factor: 79.321

4.  DNA methylation and the regulation of globin gene expression.

Authors:  M Busslinger; J Hurst; R A Flavell
Journal:  Cell       Date:  1983-08       Impact factor: 41.582

5.  The importance of the genetic picture and globin synthesis in determining the clinical and haematological features of thalassaemia intermedia.

Authors:  E Gallo; P Massaro; R Miniero; D David; C Tarella
Journal:  Br J Haematol       Date:  1979-02       Impact factor: 6.998

6.  Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea.

Authors:  G P Rodgers; G J Dover; C T Noguchi; A N Schechter; A W Nienhuis
Journal:  N Engl J Med       Date:  1990-04-12       Impact factor: 91.245

7.  5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia.

Authors:  T J Ley; J DeSimone; N P Anagnou; G H Keller; R K Humphries; P H Turner; N S Young; P Keller; A W Nienhuis
Journal:  N Engl J Med       Date:  1982-12-09       Impact factor: 91.245

8.  Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia.

Authors:  S Charache; G J Dover; M A Moyer; J W Moore
Journal:  Blood       Date:  1987-01       Impact factor: 22.113

9.  Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia.

Authors:  O S Platt; S H Orkin; G Dover; G P Beardsley; B Miller; D G Nathan
Journal:  J Clin Invest       Date:  1984-08       Impact factor: 14.808

10.  Bone marrow transplantation for thalassemia.

Authors:  G Lucarelli; E Angelucci; C Giardini; D Baronciani; M Galimberti; P Polchi; B Erer
Journal:  Indian J Pediatr       Date:  1993 Jul-Aug       Impact factor: 1.967
View more
  3 in total

1.  Experience with combination of hydroxyurea and low-dose thalidomide in transfusion-dependent beta thalassemia patients.

Authors:  Dinesh Bhurani; Jyotsna Kapoor; Neha Yadav; Vishvdeep Khushoo; Narendra Agrawal; Rayaz Ahmed; Jatinder Singh Arora; Pallavi Mehta
Journal:  Ann Hematol       Date:  2021-04-03       Impact factor: 3.673

Review 2.  Past, present & future scenario of thalassaemic care & control in India.

Authors:  Ishwar C Verma; Renu Saxena; Sudha Kohli
Journal:  Indian J Med Res       Date:  2011-10       Impact factor: 2.375

3.  Hydroxyurea Treatment in Transfusion-Dependent β-Thalassemia Patients.

Authors:  Mohammad Reza Bordbar; Samir Silavizadeh; Sezaneh Haghpanah; Roza Kamfiroozi; Marzieh Bardestani; Mehran Karimi
Journal:  Iran Red Crescent Med J       Date:  2014-06-05       Impact factor: 0.611
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.